John S. Hill

University of Alabama — United States

Medicine · Health Sciences

44h-index6.2kcitations226works1.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Photodynamic Therapy Research Studies(20), Nanoplatforms for cancer theranostics(19), International Business and FDI(17), Diabetes, Cardiovascular Risks, and Lipoproteins(15), Cholesterol and Lipid Metabolism(15)

Publications225 total

Discovery and Preclinical Development of SM15685, a Novel Highly Selective Oral DYRK1A/B Inhibitor as a Potential Therapeutic for Alzheimer’s Disease
Alzheimer s & Dementia·2024Open Access
Media Coverage of International Sport
2024
890-P: Ultraselective DYRK1A/B Inhibitors Mediated ß-Cell Proliferation and Insulin Production In Vitro and In Vivo
Diabetes·2024
A Case Study of Marcus Rashford: The People’s Champion, a “National Treasure,” and an Inspirational Personal Brand
International Journal of Sport Communication·2024· 4 cited
Abstract 5019: Next-generation DYRK1A inhibitors as a new therapeutic approach for the treatment of hematological malignancies
Cancer Research·2023· 4 cited
Supplementary Figure S3 from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma
2023Open Access
Supplementary Figure S2 from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma
2023Open Access
Supplementary Figure S3 from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma
2023Open Access
Data from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma
2023Open Access
Supplementary Figure S2 from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma
2023Open Access
Supplementary Figure S1 from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma
2023Open Access
Supplementary Figure Legends and Supplementary Table. from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma
2023Open Access
Data from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma
2023Open Access
Supplementary Figure S1 from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma
2023Open Access
Supplementary Figure Legends and Supplementary Table. from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma
2023Open Access
Supplementary Methods and Materials from A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors
2023Open Access
Data from A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors
2023Open Access
Supplementary Data from A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors
2023Open Access
Supplementary Material from First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors
2023Open Access
Data from A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors
2023Open Access
page 1 of 12Next →

Frequent Co-authors

Andrew H. Kaye(8), Jiří Fröhlich(6), P. Haydn Pritchard(5), Stanley S. Stylli(4), Howard Wong(3), Dawn Yang(3), Jan Albert Kuivenhoven(2), Michael F. Mullarkey(2), Erik Rasmussen(2), J. Fröhlich(2), D.E. Dolmans(2), Ananth Kadambi(2), Jeffrey P Walker(2), Dai Fukumura(2), Rakesh K. Jain(2), Claire Heslop(2), Leonard C. Altman(2), Nicholas J. Vardaxis(2), Don R. Phillips(2), Mark Rosenthal(2)